Study of a new drug for adults with certain blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a specific type of B-cell lymphoma (like diffuse large B-cell lymphoma, high-grade B-cell lymphoma, follicular lymphoma, or another non-Hodgkin lymphoma).
- You must have received at least two prior treatments for your lymphoma or not be eligible for other available therapies.
- Your cancer must be measurable (can be seen on scans or other tests).
- You must have completed all previous cancer treatments and recovered from their immediate side effects.
- You cannot have an active second cancer, known central nervous system involvement from lymphoma, cytomegalovirus, hepatitis B or C, uncontrolled HIV, or significant heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new combination of drugs for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.